Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/3503
Title: GDC-0941 AND CXCL8 (3-72) K11R/G31P COMBINATION THERAPY CONFERS ENHANCED EFFICACY AGAINST BREAST CANCER
Authors: Li, X.
Zhang, Y.
Walana, W.
Zhao, F.
Li, F.
Luo, F.
Keywords: breast cancer
cancer immunology
cell cycle
combination therapy
CXCR1/2
G31P
GDC-0941
metastasis
PI3K
proliferation
Issue Date: 2020
Publisher: Future Science Group
Series/Report no.: Vol.16;Issue 14
Abstract: Aim: Herein is presented the combined effect of PI3K inhibitor (GDC-0941) and CXCR1/2 analogue (G31P) in breast cancer. Materials & methods: Breast cancer cell lines and xenograft model were employed to test the efficacy of the combination therapy. Results: GDC-0941+G31P treatment substantially inhibited multi- plication of all the breast cancer cell lines used in this study (BT474, HCC1954 and 4T1). Even though single therapies caused a meaningful S-phase cell cycle arrest, the inhibition effect was more potent with the combined treatment. Similarly, enhanced apoptosis accompanied GDC-0941+G31P treatment. Further- more, the migration ability of the breast cancer cell lines were significantly curtailed by the combination therapy compared with the single treatments. Conclusion: The findings suggest that combination treat- ment involving PI3K inhibitor and CXCR1/2 analogue (G31P) could be a potent therapeutic option for breast cancer treatment.
URI: http://hdl.handle.net/123456789/3503
ISSN: 1479-6694
Appears in Collections:School of Medicine and Health Sciences



Items in UDSspace are protected by copyright, with all rights reserved, unless otherwise indicated.